Translational Oncogenomics Team
The Translational Oncogenomics team investigates how cancer evolution and plasticity lead to resistance to cancer drugs and immunotherapies, with the aim of designing better treatments that prevent drug resistance. The team was previously led by Dr Marco Gerlinger, who has now left the ICR.